1. Introduction {#sec1}
===============

Basic science has advanced our understanding of nociception and suggests numerous receptors that can be targeted by drugs for pain relief in humans. Unfortunately, few novel compounds have emerged as clinically useful analgesics ([@bib72]). Opioids are the mainstay for the management of acute pain ([@bib122]) and in palliative care ([@bib89]), where the duration of treatment is limited.

The role of opioids for the treatment of chronic non-malignant pain remains debatable ([@bib20]). Chronic pain, by definition, persists beyond 3 months. In many patients, the fluctuations in the severity of such pain are not clearly correlated with demonstrable changes in a peripheral or central disease process. There are concerns that opioid-based medications may fail to maintain their efficacy when used indefinitely to relieve such pain. Robust data on opioid treatment efficacy in these patients are lacking ([@bib77]), and concerns have grown over the escalating death rates from prescription-opioid overdose reported in the United States ([@bib79]). Nonetheless, there is still general consensus amongst clinicians, that long-term management of pain with opiates can be beneficial, or at least safe with appropriate patient selection and dose titration ([@bib16; @bib21; @bib52; @bib53]).

Opioid receptors are distributed throughout the nervous system. Experimental studies have demonstrated analgesic effects via stimulation of opioid receptors that are peripheral or centrally located ([@bib34]). There are key spinal and supraspinal actions of opioids and the latter involves descending pathways. Furthermore, recent clinical trials with methyl-naltrexone, a peripherally restricted mu-opioid-receptor antagonist, suggest that the effects within the central nervous system are important to pain relief afforded by systemic delivery of opioids in palliative care and chronic non-malignant pain ([@bib4; @bib71; @bib102]). Thus, human brain neuroimaging studies may further our understanding of the central processes through which opiates operate to provide pain relief.

Most human neuroimaging research in humans is focussed on the acute effects of opioids on experimentally induced pain in humans. Far less is known about the effects of chronic opioid analgesic therapy on the central nervous system in humans. Analgesic tolerance is a long-held limitation of chronic opioid therapy. More recent data now suggests that chronic opioid administration or withdrawal cause a hyperalgesic state ([@bib9]) where opioids can paradoxically worsen pain. Furthermore, there may be risks of cognitive decline ([@bib54]) and medication misuse, particularly in the vulnerable ([@bib84]).

Here, we discuss how far human neuroimaging research has come in translating mechanistic data from other species, suggest avenues for further studies that are relevant to the long-term management of pain with opioids.

2. Neuroimaging opioid-based analgesia {#sec2}
======================================

2.1. Acute administration of opioids {#sec2.1}
------------------------------------

Neuroimaging research suggests that the experience of pain emerges from an extensive network of brain regions ([@bib5]), which is unsurprising given how complex pain really is ([@bib104]). The International Association for the Study of Pain (IASP) defines pain as 'an unpleasant sensory or emotional experience associated with actual or potential tissue damage, or described in terms of such damage' ([@bib47]). This definition is based on the concept of pain as a specific consciousness comprising of sensory, emotional and cognitive aspects. Brain imaging has provided evidence for neural mechanisms that contribute to pain perception and its modulation, but the neuro-signature of pain itself remains elusive ([@bib106]).

Nearly all neuroimaging studies of opioid analgesia have been performed in healthy volunteers, in whom the effects of opioids on pain from brief non-injurious noxious stimuli are examined ([@bib1; @bib78; @bib86; @bib111; @bib119]). Experimentally induced pain cannot replicate the distress experienced by patients with long-term pain that is often difficult to treat. Nonetheless, studies in healthy volunteers allow for more precise stimulation of the nociceptive system and pharmacological modulation of the resultant experience of pain without illness, disease and treatment confounds. In these highly controlled experiments, short-acting intravenous opioids, for example remifentanil or alfentanil, are often employed to minimise variability from pharmacokinetics between individual subjects.

The early pharmacodynamic FMRI studies from our laboratory revealed that opioids decrease pain-related activations in a specific and dose dependent manner ([@bib119; @bib121]). Activations within the intra-calcarine cortex that are related to visual stimulation, a control task employed in these experiments, were not significantly affected by opioid administration. This finding suggests that the suppression of sensory-limbic activations was related to specific effects on neural processing, rather than global vascular effects from hypercarbia related to hypoventilation during opioid analgesia ([@bib120]). Furthermore, an investigation of the acute effects of remifentanil on FMRI activations after controlling for hypercarbia have not revealed direct effects of remifentanil on cerebral vascular reactivity itself ([@bib83]). Interestingly, we found that activations evoked within the insular regions by noxious stimuli were particularly susceptible to remifentanil ([@bib119; @bib121]). The data are consisted with the known role of insular cortex in nociception and pain perception ([@bib31; @bib69; @bib80]).

[@bib78] have further demonstrated that opioid analgesic dose response functions differ between the posterior and anterior insula cortex. In their study, the posterior insula and other regions that encode the sensory aspects of pain, also demonstrate a linear reduction of activity with increasing intravenous opioids dose. However, they report that activations in the amygdala, anterior insula and cingulate cortices, which are regions implicated in the affective aspects of pain ([@bib32]), are maximally suppressed at the lowest opioid dose. Their findings suggest that the limbic regions are exquisitely sensitive to opioid effects, consistent perhaps with their high opioid receptor densities ([Fig. 1](#fig1){ref-type="fig"}). The subjects only reported on the sensory aspects of pain in that study. Nonetheless, the FMRI data suggest that opioid analgesics can directly influence emotional responses at low doses that do not alter sensory aspects of pain ([Fig. 2](#fig2){ref-type="fig"}).

Opioid analgesia is not exclusively associated with suppression of brain activity. Wagner and colleagues found increased activation in the perigenual anterior cingulate cortex (ACC) and the periaqueductal grey (PAG) activations during opioid analgesia ([@bib111]). Converging evidence suggests that these regions comprise the neural circuit for the descending modulation of nociception, which include frontal-limbic and brainstem regions ([@bib105]). Baseline fluctuations of activity within regions in this circuit can predict moment-to-moment variation in the threshold of pain sensation within individuals, and relates to differences in trait anxiety and pain vigilance between individuals ([@bib88]). Endogenous opioids are known to contribute to the function of this descending neural circuit ([@bib13; @bib101; @bib127]). Opioids can activate this same neural circuit for analgesic effects ([@bib86]), which is shown to be active across FMRI studies during noxious stimulation itself ([Fig. 2](#fig2){ref-type="fig"}).

Interestingly, pain from noxious stimulation is also associated with activations in the several brain regions that are better known for their roles in processing rewards, such as monetary gain, palatable food, drugs and pleasurable social interactions ([@bib11]). These regions include the orbitofrontal cortex (OFC), nucleus accumbens (NA) and the ventral tegmental area (VTA), all of which are densely populated by opioid receptors. FMRI activations of these 'reward' regions during noxious stimulation may reflect increased endogenous opioidergic transmission for the regulation of pain. This increased opioidergic tone has been considered an opponent-process (pain-opposing) that persists briefly after cessation of the noxious stimulation to explain the experience of relief (from pain) ([@bib60; @bib99]). Supporting the opponent-theory of pain are studies from our group and others studies demonstrating increased activations in similar reward regions when pain relief is experienced from the cessation or diminution of noxious stimulation ([@bib8; @bib59]). More recently, we demonstrated that pain relief related to opioids could be predicted from the baseline reactivity of 'reward-regions' within the brain in an FMRI study ([@bib113]). In that study, activations within the OFC, NA and VTA evoked by painful noxious stimulation prior to opioid administration were positively correlated to reductions in subjective reports of pain intensity from identical noxious stimulation during opioid administration in healthy individuals. Opioid analgesia was also positively correlated with a psychometric measure of reward responsiveness, though neuroimaging data better accounted for the variance in opioid effects on pain ratings. Together these data suggest that opioid analgesia also involves neural mechanisms for reward processing. Interestingly, activity in these 'reward regions' evoked by noxious stimulation during opioid administration did not correlate with analgesic effect, suggesting that exogenous opioids do not directly modulate these reward regions for analgesic effect but may operate on shared mechanisms that are further downstream. For example, the baseline reactivity of the VTA also significantly predicted the opioid-induced changes in neuronal activity in the right amygdala and the left hippocampus, which may in turn influence the expression of behavioural analgesia in the study.

As with any treatment for pain, opioid analgesia can be influenced by the belief (expectancy) of efficacy held by the individual. Expectancy is often used to explain the placebo effect, which is now substantiated by neuroimaging research as a genuine psychobiological event. Endogenous opioids are known to contribute to placebo effect ([@bib98; @bib110]). Opioidergic mechanisms for placebo analgesia operate within the neural circuit for the descending control of pain, including the ACC, the PAG and the spinal dorsal horn ([@bib36]). More recently, we investigated whether effects from positive and negative expectancies of opioid analgesia engaged similar brain regions in healthy subjects ([@bib14]). The experiment involved a fixed and constant infusion of remifentanil. Subjects reported slightly lower pain compared to baseline when the infusion commenced but knowledge of that was hidden. Pain relief became significantly superior when subjects were told that the infusion had commenced. When informed that the infusion had ceased (though in reality the infusion was continued), their ratings of pain returned to baseline. The FMRI data revealed that effects of positive and negative expectancies on opioid analgesia involve *distinct* neuroanatomical substrates. Expectation of poor analgesic effect was accompanied by activation of the entorhinal cortex, a hippocampal region that mediates the exacerbation of pain through anxiety, through inhibition of perigenual ACC activity ([@bib87]). Conversely, positive expectation of analgesic effect was associated with increased perigenual ACC activation, suggesting the descending mechanisms of pain inhibition were engaged.

In addition to the areas described above that were expectancy 'specific', activations within the primary somatosensory, insular and mid-anterior cingulate cortices regions followed subjective reports of pain that was modulated by expectancy under a fixed remifentanil dose. It should be noted, though, that activations in those regions did not return to baseline levels during the nocebo arm unlike the subjectively reporting pain ratings. Hence, they reflect the true pharmacodynamic action that occurred and illustrate nicely the value of imaging that is not a simple surrogate marker of pain rating slavishly following the subjective report but are something additional. However, activations in many of these same somatosensory, insular and cingulate regions also correlate with pain modulated by varying doses of remifentanil without psychological manipulation ([@bib119; @bib121]). This raises the question about whether placebo and intrinsic opioid effects might interact significantly to impact estimates of drug effectiveness in placebo-controlled clinical trials, where a brain 'on drug' might not be able to mount the same placebo effect and mechanism as a brain 'off drug'.

[@bib6] employed a full factorial experimental design in their recent study to investigate potential interaction effects between remifentanil and expectation on pain ratings as well as brain activity. They did not find significant interaction effects on pain ratings, or brain activity. Pain relief from remifentanil and expectation were indistinguishable based on subjective pain ratings. FMRI did not reveal regions where interaction effects were significant. Instead, expectancy and remifentanil effects were distinguishable because they influenced different brain regions. Additionally, expectancy and remifentanil effects had different onsets. Expectancy effects occurred soon after the subjects became aware the infusion had started, whereas remifentanil effects become prominent only after peak blood concentrations were achieved from the infusion. These studies on drug and expectancy effects suggest that expectancy effects possess distinct functional neuro-anatomies. Further research is needed to explore the possibility of isolating the contribution of placebo or nocebo effects on pain based on neuroimaging data during clinical drug trials.

2.2. Opioid receptor availability -- PET studies {#sec2.2}
------------------------------------------------

Neuroimaging studies on the effects of opioids are scant in patients with chronic non-malignant pain. However, central effects appear critical to opioid analgesia in humans. Hence data regarding the distribution of opioid-receptors in the brain in patient populations can be instructive ([Fig. 1](#fig1){ref-type="fig"}).

Patients with chronic non-malignant pain are a heterogeneous group. Clinical trials have not revealed any particular clinical pain syndrome for which opioids are particularly efficacious. The earliest PET study suggests that opioid-receptor binding is decreased during a period of increased pain related to inflammation in a small group of patients with rheumatoid arthritis ([@bib50]). An interpretation for the decreased opioid-receptor binding observed in the longitudinal study is increased occupancy by release of brain endorphins; possibly centrally regulated pain caused by the joint inflammation.

Other investigators have employed case--control designs in their PET studies of individuals with well-characterized neuropathic pain. In general, they demonstrate decreased opioid-receptor binding in patients compared to age-matched healthy controls ([@bib51; @bib66; @bib118]). Complex regional pain syndrome (CRPS) and fibromyalgia are currently diagnoses of exclusion: the contributing pathologies remain unclear in symptomatic individuals. In these pain syndromes, opioid-receptor binding is again altered primarily in the frontal and limbic regions, and further accounts in part for the variance observed in the self-reports of affect and mood related to pain in patients ([@bib44; @bib56]).

A reduced opioid-receptor density has been proposed as an explanation for the efficacy of exogenous opioids or the lack thereof in patients ([@bib44; @bib66]). However, binding potential is an estimate of available receptors, which depends on the affinity and selectivity of ligand ([@bib46]). A change in binding potentials may be related to receptor occupancy by endogenous opioid peptides or change in absolute quantity of receptors. Additionally, the action of different opioids varies depending on the selectivity of their binding to opioid-receptor subtypes ([@bib70]).

3. Opioid tolerance and drug-induced hyperalgesia {#sec3}
=================================================

3.1. Analgesic tolerance {#sec3.1}
------------------------

Opioid-induced tolerance is simply described as a shift to the right in the dose--response curve: a higher dose is required over time to maintain analgesic effect. Progressive disease may lead to higher opioid requirements. Tolerance also results from pharmacokinetic change, for example, when the drug up-regulates the activity of a metabolic process that facilitates its elimination from the body. For this review, "opioid tolerance" refers to pharmacodynamic tolerance, which reflects drug-activated changes in the response of the neural systems.

Mechanisms for analgesic tolerance include altered molecular signalling pathways and down-regulation of opioid receptors ([@bib74]). These mechanisms are largely elucidated in *healthy* animal models. Data regarding opioid tolerance in animal models of inflammation, injury and disease are few and inconsistent. Some behavioural studies suggest that tolerance to the anti-nociceptive effects (withdrawal effects) of opioids develop more slowly in inflammatory ([@bib108; @bib126]), cancer ([@bib107]) and neuropathic models ([@bib48]) when compared to sham controls. Other studies demonstrate enhanced development of analgesic tolerance, particularly in neuropathic models ([@bib92]). The inconsistencies appear related to the species, disease model and the opioid and dose administered ([@bib72]).

3.2. Opioid-induced hyperalgesia {#sec3.2}
--------------------------------

Distinct from tolerance, the *excitatory* effects of opioids at the cellular level are thought to cause opioid-induced hyperalgesia ([@bib73; @bib100; @bib109; @bib114]). In clinical practice, opioid-induced hyperalgesia is diagnosed when generalised pain develops and worsens with escalating opioid dose ([@bib103]). Improvement following opioid dose reduction is recommended to help distinguish between opioid tolerance and excitatory effects ([@bib10]). However, discomfort related to drug withdrawal can negatively influence the overall pain experienced and cloud the diagnosis.

Opioid-induced hyperalgesia is mainly demonstrated after prolonged administration of opioids in healthy animal models ([@bib9; @bib45]). These data appear consistent with findings of decreased tolerance of noxious stimuli in human individuals maintained on long-term methadone to manage opioid dependence ([@bib27; @bib35; @bib90]). However, a recent study in which oxycodone was administered orally over days in healthy volunteers without a history of drug misuse revealed no analgesic tolerance or hyperalgesia ([@bib29]). Hence, the development of tolerance or hyperalgesia may vary with the duration of administration, dose and opioid chemistry ([@bib2]).

Susceptibility to these hyperalgesic drug effects may also differ between individuals. In healthy volunteers, cessation of remifentanil (after about 40 min of infusion) can induce ([@bib49; @bib64; @bib112]) or enhance hyperalgesia ([@bib3; @bib85]) but not consistently. The phenomenon of opioid post-infusion hyperalgesia has been investigated recently in a combined psychophysical-fMRI study ([@bib112]). Only half of all subjects recruited developed post-infusion hyperalgesia to noxious thermal stimuli, implying considerable inter-individual variation for the phenomenon, possibly related to genetic susceptibility ([@bib49]). Midbrain reticular formation activation was significantly increased only in hyperalgesic subjects but correlated negatively with the degree of hyperalgesia, which suggest that brainstem activity regulates, rather than drives sensitisation effects during opioid withdrawal.

In that human FMRI study ([@bib112]), subjects who developed opioid post-infusion hyperalgesia were indistinguishable from the rest of study cohort during the remifentanil infusion itself: decreases in subjective ratings of pain during opioid infusion were similar in both groups. In subjects who subsequently developed post-infusion hyperalgesia, FMRI revealed increased activation in the midbrain reticular formation during the opioid infusion, suggesting initiation of pro-nociceptive process in that brief period. This was an acute administration study with an hour of opioid infusion, it remains unclear whether opioid-induced hyperalgesia would have occurred eventually had the infusion been prolonged in the susceptible individuals.

3.3. Opioid-induced hyperalgesia in injury or disease {#sec3.3}
-----------------------------------------------------

In contrast to opioid-induced hyperalgesia in healthy animals, relatively few animal studies demonstrate opioid-induced hyperalgesia in the presence of tissue injury ([@bib18; @bib62; @bib63]), inflammation ([@bib95]) or cancer ([@bib55]), suggesting that these pathological states are protective. Notably, the doses of opioids used to induce hyperalgesia appear higher than those employed to study opioid tolerance.

Several clinical investigators have reported increased post-surgical pain scores and analgesic requirements following intra-operative remifentanil administration ([@bib43; @bib93]). However, the effects are small and are not reproduced in other comparable studies ([@bib30; @bib58]), leading to questions about the relevance of opioid tolerance or withdrawal-induced hyperalgesia in peri-operative pain management ([@bib41]). Quantitative sensory testing in patients whose pain is managed by chronic opioid therapy reveals decreased pain thresholds to noxious stimuli during opioid therapy ([@bib19; @bib22]) but not consistently ([@bib94]). Again, the findings are difficult to interpret, as the patients were heterogeneous in terms of pain phenotypes. Also, the relevance of QST findings to the clinical pain state is yet to be fully established.

4. Pain and opioid addiction {#sec4}
============================

4.1. Opioid self-administration {#sec4.1}
-------------------------------

In laboratory settings, unrestrained and healthy rats exposed to morphine by chance will subsequently self-administer opiates regularly ([@bib42]). This behavioural model has long been employed as a tool for studying neurobiology of addiction ([@bib116]). There are less data on how inflammatory or neuropathic pain might modulate volitional opioid self-administration. Rats with experimental arthritis increase opioid self-administration with progression of inflammation. Opioid self-administration decreased with alleviation of inflammation by indomethacin or dexamethasone treatment ([@bib23; @bib24; @bib65]). Also, opiates do not seem to act as reinforcers in neuropathic models of pain ([@bib81; @bib82]). Sustained activation of the kappa-opioidergic system within the nucleus accumbens is observed in the inflammatory pain state, and is thought to suppress drug-rewarding effects ([@bib75]).

More recently, Ewan and colleagues compared the effects of morphine and cocaine on intracranial electrical self-stimulation (ICSS) of the VTA in the nerve-ligated rat, a model of neuropathic pain ([@bib37]). ICSS is an operant paradigm in which rats will press a lever repeatedly in order to receive intracranial electrical stimulation, which is highly rewarding by itself. In healthy rats, cocaine and opioids facilitated ICSS. In contrast, cocaine facilitated ICSS in nerve-ligated rats but opioids, which produced analgesic effects, did not. A subsequent experiment by the same investigators revealed opposite effects of these drugs on ICSS of the paraventricular nucleus (PVN) of the hypothalamus: opioids facilitate ICSS to a greater extent than cocaine ([@bib38]). Their studies reveal the complex interaction between opioid analgesia and reward-seeking behaviour. The reinforcing properties of opioids are modulated by neuropathic pain and appear to be mediated differently from those of cocaine, a clearly non-analgesic but addictive drug.

Overall, the experimental data suggest that opioids do not act as primary reinforcers in the presence of pain that is clearly attributable to peripheral or central pathology. This is consistent with the bulk of clinical experience of opioid use for post-surgical ([@bib122]), and cancer-related pain ([@bib89]).

4.2. Subjective effects of opioids {#sec4.2}
----------------------------------

The positive subjective effects induced by opioids are thought to be reinforcing in humans but there is evidence that pain modulates these effects. In healthy subjects without clinical pain or history of recreational drug dependence, positive subjective effects of opioids are decreased during pain caused by hand-immersion in icy-cold water ([@bib28; @bib124]). The subjective effects of opioids may differ in the presence of chronic pain, or when there is continued exposure of opioids. An early study in the 1950s reported that in contrast to healthy controls and in the opioid dependent subjects, most chronically ill patients reported the drug as pleasant only because it reduced pain ([@bib57]). A later study found that opioid-dependent subjects reported more positive effects ('Liking' and 'Good drug effects'), and had lower ratings for negative effects ('Coasting' and "Tired or sluggish') ([@bib7]).

The rate of drug delivery to the central nervous system is widely held to be a key predictor of the reinforcing strength of a drug. Extensive data in non-human species suggest that rapid delivery is associated with increased addictive potential for several recreational drugs, including opioids ([@bib96]). In humans, under well-controlled experimental settings, more rapid infusions of opioids produced increased positive effects of the drug in healthy volunteers ([@bib67]) as well as opioid-dependent subjects ([@bib25]). It remains unclear whether the positive subjective reactions of rapid drug administration are modulated in the presence of pain. Also subjective reactions to opioids do not themselves explain differences in self-administration in the presence of a painful stimulus. A recent study found that opioid use was linked to the presence of painful stimulation in the control group but not in the drug-dependent group even though the positive subjective effects of opioids (oxycodone) were similar in opioid-dependent and control groups ([@bib26]).

4.3. Neuroimaging the subjective effect of opioids {#sec4.3}
--------------------------------------------------

Neuroimaging research has largely focussed on the analgesic effect of opioids. There are relatively few data on the neural correlates of subjective or reinforcing effects of opioids per se in healthy drug-naïve volunteers. Several PET studies have revealed significant changes in regional cerebral blood flow particularly in the ACC and OFC following acute administration (single dose) of opioids in healthy volunteers ([@bib40]). Similar activity is observed in other MR-perfusion-based studies ([@bib61; @bib125]).

These changes might be anticipated given the distribution of opioid receptors in the brain, and are likely neural correlates to the subjective effects of the drug in the absence of pain ([@bib61; @bib125]).

4.4. Opioids and the brain in chronic pain {#sec4.4}
------------------------------------------

There are as yet no published data regarding how the brains of patients with pain respond to long-term opioid therapy. The decreased opioid receptor binding in PET studies suggest that brain responses to opioids should differ and account for clinically relevant effects (see previous section). Further support for the hypothesis comes from the numerous MR-based studies that suggest volumetric changes in the reward-circuitry in several clinical pain populations compared to healthy controls ([@bib97]). However, it remains unclear whether these findings from neuroimaging (PET or MRI) studies relate to chronic pain or to effects from long-term medication use (including opioids).

The issue was partly addressed in a recent longitudinal MR study ([@bib123]). Individuals with chronic low back pain were administered oral morphine daily for 1 month, and compared to those who used placebo. Significant volumetric differences were observed in several regions, including the amygdala, and anterior cingulate cortex between patients who were treated with opioids compared to those who received placebo. However, patients who were treated with morphine reported significant reduction of reported pain scores, compared to those who were on placebo. Thus, the MR findings may relate to pain relief in general, rather than to the effects of opioid specifically. Interestingly, the volumetric changes in the morphine group persisted for months after cessation of opioids but no data regarding pain at that stage were reported.

It is still unclear whether structural changes in the limbic system determine the subjective effects of exogenous opioids. A recent FMRI study explored activity in the NA in patients with chronic back pain ([@bib8]). This limbic structure forms part of the mesostriatal dopamine pathway of the reward-circuitry. It encodes information that helps determine motivation and hence the behavioural response to external stimuli ([@bib60]). In that study, noxious heat stimulation engendered NA responses in patients with chronic pain that were diametrically opposite to those of controls suggesting differences in motivational value assigned to the experimental stimulus. Whether these findings generalise to other salient stimuli, or influence the reinforcing effects of exogenous opioids await further investigation.

5. Future directions {#sec5}
====================

The goals of healthcare are to improve comfort, psychosocial function, and longevity. Pain relief or comfort from opioid therapy does not necessarily lead to improvements in other aspects of health. Adverse effects can lead to significant physical deterioration and unintended respiratory depression and death can occur when opioid therapy is poorly monitored ([@bib15; @bib115]). Tolerance and opioid-induced hyperalgesia further limits the *effectiveness* of opioid-based analgesia in patients. Current animal data do show that tolerance and hyperalgesia are slow to develop in the presence of overt pathology that induces pain. However, the direct relevance of these mechanistic data for clinical practice remains to be established. Consequently, caution is being urged when initiating or escalating opioid therapy in patients for pain that is disproportionate to the disease process, or in the pain syndromes where pathology cannot as yet be demonstrated ([@bib76]). Addictive potential is now cited as a concern when opioids are used for treating chronic non-malignant pain ([@bib33; @bib79]). However, defining or diagnosing opioid misuse in patients with pain remains perplexing ([@bib117]) and currently relies on behaviour that is also observed when pain is poorly treated ([@bib12]). Physicians are expected to distinguish between the use of opioids as 'medications to relieve pain', and the illegitimate use of opioids as 'drugs to get high'([@bib39]). Unfortunately, there is no objective tool that can clarify motivation for opioid use in patients with pain. Opioids are intrinsically rewarding, but so is pain relief ([@bib59]) achieved through its use. Disambiguating these effects in patients with pain can be challenging. In-vivo human neuroimaging studies of opioid pharmacology now exist, but most data pertain to single dose opioids in healthy volunteers. There is a clear need for studies that are relevant to the complex issues clinicians face in prescribing long-term opioids for analgesia ([@bib17]).

![Opioid receptor distribution in the human brain. \[Above\] The distribution of opiate receptors in the medial and lateral aspects of brain is revealed by an in-vivo study of opiate binding potential using radiolabeled carfentanil, a mu-opiate receptor ligand. There is increased binding in the frontal-limbic relative to sensory regions ([@bib91]). \[Below\] Axial sections showing the gross anatomy (left) and radio-ligand binding to mu opiate receptors. Note the high opioid receptor densities in the insular region ([@bib68]). Courtesy of Professor Bruce Morton.](gr1){#fig1}

![Brain mechanisms of opioid analgesia. Pain perception is generated by neural activation in the inter-connected (light-grey arrows) brain regions that have sensory-discriminatory (blue) and affective-motivational (red) functions. Opioids may alter the consciousness of pain directly by preferential targeting of limbic regions (in red box). Additionally, opioids may engage limbic-brainstem inhibition of spinal nociception (dark grey arrows), which also occurs during cognitive control of pain that involves the prefrontal cortex (PFC).](gr2){#fig2}
